drugset / Trial / NCT05362110

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

NCT05362110

Phase 3 Completed 361 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension

Timeline

Start
2022-05-16
Primary completion
2023-06-05
Completion
2023-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1803-3 Unknown Oral
Comparator RLD2002 Unknown Oral